Intervention Review

You have free access to this content

Chemotherapy versus best supportive care for extensive small cell lung cancer

  1. Marta Pelayo Alvarez1,*,
  2. Virginie Westeel2,
  3. Marcela Cortés-Jofré3,
  4. Xavier Bonfill Cosp4

Editorial Group: Cochrane Lung Cancer Group

Published Online: 27 NOV 2013

Assessed as up-to-date: 17 OCT 2013

DOI: 10.1002/14651858.CD001990.pub3


How to Cite

Pelayo Alvarez M, Westeel V, Cortés-Jofré M, Bonfill Cosp X. Chemotherapy versus best supportive care for extensive small cell lung cancer. Cochrane Database of Systematic Reviews 2013, Issue 11. Art. No.: CD001990. DOI: 10.1002/14651858.CD001990.pub3.

Author Information

  1. 1

    Conselleria Valenciana, Atención Primaria Área 11, Valencia, Spain

  2. 2

    University Hospital of Besançon, Thoracic Oncology, Besançon, France

  3. 3

    Programa Doctorado en Ciencias Médicas, Universidad de La Frontera, Facultad de Medicina, Universidad Católica de la SS. Concepción, Concepción, VIII, Chile

  4. 4

    CIBER Epidemiología y Salud Pública (CIBERESP), Spain - Universitat Autònoma de Barcelona, Iberoamerican Cochrane Centre, Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Catalonia, Spain

*Marta Pelayo Alvarez, Atención Primaria Área 11, Conselleria Valenciana, Valencia, Spain. MPelayo@Hospital-Ribera.com.

Publication History

  1. Publication Status: New search for studies and content updated (no change to conclusions)
  2. Published Online: 27 NOV 2013

SEARCH

References

References to studies included in this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
  4. References to other published versions of this review
Ciuleanu 2010 {published data only}
  • Ciuleanu T, Samarzjia M, Demidchik Y, Beliakouski V, Rancic M, Bentsion DL, et al. Randomized phase III study (SPEAR) of picoplatin plus best supportive care (BSC) or BSC alone in patients (pts) with SCLC refractory or progressive within 6 months after first-line platinum-based chemotherapy. Journal of Clinical Oncology (ASCO) 2010;28(15 Suppl):7002.
Kokron 1977b {published data only}
  • Kokron O, Titscher R, Micksche M, Cerni C, Wrba H. Clinical experiences with Holoxan in small ceIl carcinoma of the bronchus (authors transl). Osterreichische Kneipp Magazin 1977;15:103-8.
Kokron 1982 {published data only}
  • Kokron O, Mickshe M, Titscher R, Wrba H. Ifosfamide versus ifosfamide + CCNU in the treatment of inoperable small celI lung cancer. A clinical study. Onkologie 1982;56:56-9.
O'Brien 2006 {published data only}
  • O'Brien MER, Ciuleanu TE, Tsekov H, Shparyk Y, Cucevia B, Juhasz G, et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. Journal of Clinical Oncology 2006;24:5441-7.
O'Brien 2007a {published data only}
  • O'Brian ME, Duh MS, Chen L, Antras L, Neary M, Gralla RJ. An analysis of disease control: is major response associated with greater symptomatic benefits than stable disease in small cell lung cancer (SCLC)? Results from the randomised Oral Topotecan (OT) vs. Best Supportive Care (BSC) trial: P1-224. Journal of Thoracic Oncology 2007;2(8):S827.
Spiro 1989 {published data only}
  • Spiro SG, Souhami RL, Geddes DM, Ash CM, Quinn H, Harper PG, et al. Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. British Journal of Cancer 1989;59:578-83.

References to studies excluded from this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
  4. References to other published versions of this review
AlIan 1984 {published data only}
  • Allan SG, Gregor A, Cornbleet MA, Leonard RC, Smyth JF, Grant IW, et al. Phase II trial of vindesine and VP16-213 in the palliation of poor-prognosis patients and elderly patients with small cell lung cancer. Cancer Chemotherapy and Pharmacology 1984;13:106-8.
Anderson 1993 {published data only}
  • Anderson FI, Hopwood P, Prendiville J, Radford JA, Thatcher N, Ashcroft L. A randomised study of bolus vs continuous pump infusion of ifosfamide and doxorubicin with oral etoposide for small cell lung cancer. British Journal of Cancer 1993;67:1385-90.
Ardizzoni 2002 {published data only}
  • Ardizzoni A, Tjan-Heijnen VCG, Postmus PE, Buchholz E, Biesma B, Karnicka Mlodkowska FI, et al. Standard versus intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: A prospective European Organization for Research and Treatment of Cancer-Lung Cancer Group phase III trial-08923. Journal of Clinical Oncology 2002;20:3947-55.
Beith 1996 {published data only}
  • Beith JM, Clarke SJ, Woods RL, Bell DR, Levi JA. Long-term follow-up of a randomised trial of combined chemoradiotherapy induction treatment, with and without maintenance chemotherapy in patients with small cell carcinoma of the lung. European Journal of Cancer 1996;32A:438-43.
Bleehen 1989 {published data only}
  • Bleehen NM, Fayers PM, Girling DJ, Stephens RJ. Controlled trial of twelve versus six courses of chemotherapy in the treatment of small cell lung cancer. British Journal of Cancer 1989;59:584-90.
Bleehen 1993 {published data only}
  • Bleehen NM, Girling DJ, Machin D, Stephens RJ. A randomised trial of three or six courses of etoposide, cyclophosphamide, methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (SCLC). II: Quality of life. Medical Research Council Lung Cancer Working Party. British Journal of Cancer 1993;68:1157-66.
Bleehen 1996 {published data only}
  • Bleehen NM, Girling D, Hopwood P, Lallemand G, Machin D, Stephens RI, et al. Randomised trial of four-drug vs less intensive two-drug chemotherapy in the palliative treatment of patients with small-cell lung cancer (SCLC) and poor prognosis. British Journal of Cancer 1996;73:406-13.
Candido 2002 {published data only}
  • Candido P, Cavallaro G, Piatti G, Bucchioni E. Results of a combined phase II study on small celI lung cancer. Giornale Italiano Delle Malattie del Torace 2002;56:105-12.
Chen 2007 {published data only}
  • Chen L, Antras L, Duh MS, Pickard S, Cella D, Neary M, et al. Is treatment with oral topotecan plus best supportive care associated with better health status compared to best supportive care alone in small cell lung cancer?: D1-06. Journal of Thoracic Oncology 2007;2(8):S391-2.
Ciuleanu 2002 {published data only}
  • Ciuleanu TE, Curca R, Iancu D, Todor N, Cebotaru C, Fadulescu I, et al. First-Iine chemotherapy with topotecan and etoposide in advanced small cell lung cancer. A phase II study. Journal of the Balkan Union of Oncology 2002;7:43-6.
CuIlen 1986 {published data only}
  • Cullen M, Morgan D, Gregory W, Robinson M, Cox D, McGivern D, et al. Maintenance chemotherapy for anaplastic small celI carcinoma of the bronchus: a randomised, controlled trial. Cancer Chemotherapy and Pharmacology 1986;17:157-60.
EarI 1991 {published data only}
  • Earl HM, Rudd RM, Spiro SG, Ash CM, James LE, Law CS, et al. A randomised trial of planned versus as required chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. British Journal of Cancer 1991;64:566-72.
Eridani 1978 {published data only}
  • Eridani S, Burdick L, Maggio L, Cunietti E, Periti M, Arosio A, et al. Combined chemotherapy for unresectable carcinoma of the lung: a randomised trial. International Journal of Clinical Pharmacology & Biopharmacy 1978;16:182-5.
Ettinger 1990 {published data only}
  • Ettinger DS, Finkelstein DM, Abeloff MD, Ruckdeschel JC, Aisner SC, Eggleston JC. A randomised comparison of standard chemotherapy versus alternating chemotherapy and maintenance versus no maintenance therapy for extensive-stage small-cell lung cancer: a phase III study of the Eastern Cooperative Oncology Group. Journal of Clinical Oncology 1990;8:230-40.
Garassino 2011 {published data only}
  • Garassino MC, Torri V, Michetti G, Lo Dico M, La Verde N, Sglione S, et al. Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: A multi-institutional retrospective analysis. Lung Cancer 2011;72:378-83.
Giaccone 1993 {published data only}
  • Giaccone G, Dalesio O, McVie GJ, Kirkpatrick A, Postmus PE, Burghouts JT, et al. Maintenance chemotherapy in small cell lung cancer: long-term results of a randomised trial. Journal of Clinical Oncology 1993;11:1230-40.
Green 1969 {published data only}
GrideIIi 2002 {published data only}
  • Gridelli C, Rossi A, Barletta E, Panza N, Brancaccio L, Cioffi R, et al. Carboplatin plus vinorelbine plus G-CSF in elderly patients with extensive-stage small-cell lung cancer: a poorly tolerated regimen. Results of a multi-centre phase II study. Lung Cancer 2002;36:327-32.
Hainsworth 2002 {published data only}
Hanna 2002 {published data only}
  • Hanna NH, Sandler AB, Loehrer PJ, Ansari R, Jung SH, lane K, et al. Maintenance daily oral etoposide versus no further therapy following induction chemotherapy with etoposide plus ifosfamide plus cisplatin in extensive small-cell lung cancer: a Hoosier Oncology Group randomised study. Annals of Oncology 2002;13:95-102.
James 1996 {published data only}
  • James LE, Gower NH, Rudd RM, Spiro SG, Harper PG, Trask CW, et al. A randomised trial of low-dose/high-frequency chemotherapy as palliative treatment of poor-prognosis small-ceIl lung cancer: a Cancer Research Campaign trial. British Journal of Cancer 1996;73:1563-8.
Joss 1995 {published data only}
  • Joss RA, Alberto P, Hurny C, Bacchi M, Leyvraz S, Thurlimann B, et al. Quality versus quantity of life in the treatment of patients with advanced small-cell lung cancer? A randomised phase III comparison of weekly carboplatin and teniposide versus cisplatin, adriamycin, etoposide alternating with cyclophosphamide, methotrexate, vincristine and lomustine. Swiss Group for Clinical Cancer Research (SAKK). Annals of Oncology 1995;6:41-8.
Kokron 1974a {published data only}
  • Kokron O. [Die Behandlung des kleinzelligen metastasierenden Bronchuskarzinoms mit Ifosfamid. Ergebnisse einer prospectiven randomisierten Studie]. Österreichische Zeitschrift für Onkologie 1974;5-6:123-7.
Kokron 1974b {published data only}
  • Kokron O. Treatment of oat cell metastazing bronchial carcinoma with isofosfamide. Results of a prospective randomised study [Die Behandlung des kleinzelligen Bronchuskarzinoms]. Osterreichische Kneipp Magazin 1974;5-6:123-7.
Kokron 1977a {published data only}
  • Kokron O. [Klinische Erfahrungen mit Holoxan beim kleinzelligen Bronchuskarzinom]. Österreichische Zeitschrift für Onkologie 1977;4:103-6.
Korfel 2002 {published data only}
  • Korfel A, Oehm C, von Pawel J, Keppler U, Deppermann M, Kaubitsch S, et al. Response to topotecan of symptomatic brain metastases of small-cell lung cancer also after whole brain irradiation. A multi-centre phase II study. European Journal of Cancer 2002;38:1724-9.
Lebeau 1992 {published data only}
  • Lebeau B, Chastang Cl, Allard P, Migueres J, Boita F, Fichet D, et al. Six vs twelve cycles for complete responders to chemotherapy in small cell lung cancer: definitive results of a randomised clinical trial. European Respiratory Journal 1992;5:286-90.
Lyss 2002 {published data only}
  • Lyss AP, Herndon lI JE, Lynch Jr TJ, Turrisi AT, Watson DM, Grethlein SJ, et al. Novel doublets in extensive-stage small-cell lung cancer: A randomised phase II study of topotecan plus cisplatin of paclitaxel (CALGB 9430). Clinical Lung Cancer 2002;3:205-10.
Mattson 1992 {published data only}
  • Mattson K, Niiranen A, Pyrhönen S, Holsti LR, Holsti P, Kumpulainen E, et al. Natural interferon alfa as maintenance therapy for small cell lung cancer. European Journal of Cancer 1992;28A:1387-91.
Mattson 1997 {published data only}
  • Mattson K, Niiranen A, Ruotsalainen T, Maasilta P, Halme M, Pyrhönen, et al. Interferon maintenance therapy for small cell lung cancer: improvement in long-term survival. Journal of Interferon and Cytokine Research 1997;17:103-5.
Maurer 1980 {published data only}
Mok 2002 {published data only}
Naka 2002 {published data only}
  • Naka N, Kawahara M, Okishio K, Hosoe S, Ogawara M, Atagi S, et al. Phase II study of weekly irinotecan and carboplatin for refractory or relapsed small-cell lung cancer. Lung Cancer 2002;37:319-23.
Noda 2002 {published data only}
  • Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. New England Journal of Medicine 2002;346:85-91.
Reck 1998 {published data only}
  • Reck M, Haering B, Koschel G, Kaukel E, Von Pawel J, Gatzemeier U. Chemotherapy of advanced SCLC and NSCLC with Bendamustine - A phase II-study. Pneumologie 1998;52:570-3.
Rosenthal 1991 {published data only}
Schiller 2001 {published data only}
  • Schiller JH, Adak S, Cella D, DeVore RF, Johnson DH. Topotecan versus observation alter cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593 - A phase III trial of the Eastern Cooperative Oncology Group. Journal of Clinical Oncology 2001;19:2114-22.
Sculier 1996 {published data only}
  • Sculier JP, Paesmans M, Bureau G, Giner V, Lecomte J, Michel J, et al. Randomized trial comparing induction chemotherapy versus induction chemotherapy followed by maintenance chemotherapy in small-cell lung cancer. Journal of Clinical Oncology 1996;14:2337-44.
Smit 1989 {published data only}
Souhami 1997 {published data only}
  • Souhami RL, Spiro SG, Rudd RM, Ruiz de Elvira MC, James LE, Gower NH, et al. Five-day oral etoposide treatment for advanced small-cell lung cancer: randomised comparison with intravenous chemotherapy. Journal of the National Cancer Institute 1997;89:577-80.
Sundstrom 2002 {published data only}
  • Sundstrom S, Bremnes RM, Kaasa S, Aasebo U, Hatlevoll R, Dahle R, et al. Norwegian Lung Cancer Study Group. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomised phase III trial with 5 years follow-up. Journal of Clinical Oncology 2002;20:4665-72.
Tada 2002 {published data only}
  • Tada A, Ueoka H, Kiura K, Tabata M, Takemoto M, Yamane H, et al. Combination chemotherapy with carboplatin and etoposide for elderly patients aged 76 years or older with small cell lung cancer. [Japanese]. Gan to Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy] 2002;29:751-6.
Thatcher 1996 {published data only}
  • Thatcher N, Clark PI, Girling DJ, Hopwood P, Twiddy S, Stephens RJ, et al. Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: A stopped multi-centre randomised trial. Lancet 1996;348:563-6.
Thomas 2002 {published data only}
  • Thomas JP, Moore T, Kraut EH, Balcerzak SP, Galloway S, Vandre DD. A phase II study of CI-980 in previously untreated extensive small celI lung cancer: an Ohio State University phase II research consortium study. Cancer Investigation 2002;20:192-8.
Tjan-Heíjnen 2001 {published data only}
  • Tjan-Heijnen VCG, Postmus PE, Ardizzoni A, Manegold Ch, Burghouts J, Van-Meerbeeck J, et al. Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: An EORTC double-blind placebo-controlled phase III study. Annals of Oncology 2001;12:1359-68.
Vanseenkiste 2001 {published data only}
  • Vansteenkiste J, Gatzemeier U, Manegold C, Hanauske A, Weynants P, Bosquée L, et al. Gemcitabine plus etoposide in chemo-naive extensive disease small-ceIl lung cancer: A multi-centre phase II study. Annals of Oncology 2001;12:835-40.
von Pawel 1990 {published data only}
  • von Pawel J, Wilke H, Vahee D, Dimbeck H, Schmohl HJ. Phase II study with etoposide/vincristine in small cell bronchial cancer (extensive disease), [Article in German]. Pneumologie 1990;44:582-3.
Zhang 2002 {published data only}
  • Zhang Z, Hu Z, Lu X, Zeng L. Evaluation of topotecan combined with cisplatin in the treatment of small cell Iung cancer. Chinese Journal of Lung Cancer 2002;5:354-6.

Additional references

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
  4. References to other published versions of this review
Amarasena 2009
  • Amarasena IU, Walters JAE, Wood-Baker R, Fong K. Platinum versus non-platinum chemotherapy regimens for small cell lung cancer. Cochrane Database of Systematic Reviews 2008, Issue 4. [DOI: 10.1002/14651858.CD006849.pub2]
Bell 2013
  • Bell M, Kenward MG, Fairclough DL, Horton NJ. Differential dropout and bias in randomised controlled trials: when it matters and when it may not. BMJ 2013;346:e8668.
Bernhard 1996
  • Bernhard J, Hürny C, Bacchi M, Joss RA, Cavalli F, Senn HJ, et al. Initial prognostic factors in small-celI lung cancer patients predicting quality of life during chemotherapy. British Journal of Cancer 1996;74:1660-7.
Carney 2002
Cheng 2007
  • Cheng S, Evans WK, Stys-Norman D, Shepherd FA, the Lung Cancer Disease Site Group of Cancer Care Ontario' Program in Evidence-based Care. Chemotherapy for relapse small cell lung cancer: a systematic review and practice guideline. Journal of Thoracic Oncology 2007;2:348-54.
Chutte 1999
  • Chute J, Chen T, Feigal E, Simon R, Johnson B. Twenty years of phase III trials for patients with extensive-stage small celI lung cancer: perceptible progress. Journal of Clinical Oncology 1999;17:1794-801.
Ciani 2013
  • Ciani O, Buyse M, Garside R, Pavey T, Stein K, Sterne J, et al. Comparison of treatment effect sizes associated with surrogate and final patient relevant outcomes in randomised controlled trials: meta-epidemiological study. BMJ 2013;346:457-69.
Cortés-Jofré 2012
Day 2000
De Vita 2000
  • De Vita V, Hellan S, Rosemberg S. Cancer: Principles & Practice of Oncology. Sixth. Philadelphia: Lippincott, 2000.
De Wet 1994
  • De Wet M, Falkson G, Rapoport BL. Small cell Iung cancer: analysis of factors influencing the response to treatment and survival. Oncology 1994;51:523-34.
Dumville 2006
Govindan 2006
  • Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. Journal of Clinical Oncology 2006;24:4539-44.
Gralla 2004
  • Gralla RJ. Quality of life considerations in patients with advanced lung cancer: effect of topotecan on symptom palliation and quality of life. The Oncologist 2004;9 Suppl 6:14-24.
Higgins 2011
  • Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011].. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
Hollen 1994a
Hollen 1994b
Ihde 1992
  • Ihde DC. Chemotherapy of lung cancer. New England Journal of Medicine 1992;327:1434-41.
Kim 2008
Kleinbaum 1996
Lacombe 1997
Lassen 1998
  • Lassen, Hirsch FR, Osterlind K, Bergman B, Dombernoswky P. Outcome of combination chemotherapy in extensive stage small-celI lung cancer: any treatment related progress?. Lung Cancer 1998;20:151-60.
Loveman 2010
  • Loveman E, Jones J, Hartwell D, Bird A, Harris P, Welch K, Clegg A. The clinical effectiveness and cost-effectiveness of topotecan for small cell lung cancer: a systematic review and economic evaluation. Health Technological Assessment 2010;14(19):1-6.
Lundh 2012
  • Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L. Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews 2012, Issue 12.
Manser 2010
Moore 1998
  • Moore RA, Gevaghan D, Traver MR, Collins S, McQuay HJ. Size is everything. The impact of event rate variation on clinical trials and meta-analysis. Pain 1998;78:208-16.
Owonikoko 2007
  • Owonikoko TK, Ragin CC, Belani ChP, Oton AB, Gooding WE, Taioli E, et al. Lung cancer in elderly patients: an analysis of the Surveillance, Epidemiology, and End Results Database. Journal of Clinical Oncology 2007;25:5570-7.
Oze 2009
  • Oze I, Hotta K, Kiura K, Ochi N, Takigawa N, Fujiwara Y, et al. Twenty-seven years of phase III trials for patients with extensive disease small-cell lung cancer: disappointing results. PLOS ONE 2009;4:e7835.
Rawson 1990
  • Rawson NS, Peto J. An overview of prognostic factors in small cell Lung cancer. A report from the Subcommittee for the Management of Lung Cancer of the United Kingdom Coordinating Committee on Cancer Research. British Journal of Cancer 1990;61:597-604.
Riaz 2012
  • Riaz PS, Lüchtenborg M, Coupland HV, Spicer J, Peake DM, Moller H. Trends in incidence of small cell lung cancer and all lung cancer. Lung Cancer 2012;75:280-4.
Riemsma 2010
  • Riemsma R, Simons JP, Bashir Z, Gooch CL, kleijnen J. Systematic review of topotecan (Hycamtin) in relapsed small cell lung cancer. BMC Cancer 2010;10:436-48.
Rothwell 2005
Seidenfeld 2006
  • Seidenfeld J, Samson  DJ, Bonnell CJ, Ziegler KM, Aronson N. Management of small cell lung cancer. Evidence Report/Technology Assessment No 143. AHRQ Publication No. 06-E016. Rockville, MD: Agency for Health Research and Quality July 2006.
Souhami 1988
  • Souhami RL, Morittu L, Ash CM, EarI H, Geddes D, Harper PG, et al. Identification of patients at high risk of chemotherapy induced toxicity in SCLC. Antibiotics and Chemotherapy 1988;41:220-5.
Souhami 1990
  • Souhami RL, Law K. Longevity in small cell lung cancer. A report to the Lung Cancer SubCommitee of the United Kingdom Coordinating Commitee for Cancer Research. British Journal of Cancer 1990;61:584-9.
Sugiyama 2008
  • Sugiyama T, Hirose T, Hosaka T, Kusumoto S, Nakashima M, Yamaoka T, et al. Effectiveness of intensive follow-up after response in patients with small cell lung cancer. Lung Cancer 2008;59:255-61.
Sundstr¢m 2005
  • Sundstr¢m S, Bremnes RM, Kaasa S, Aaseb¢ U, Aamdal S. Second-line chemotherapy in recurrent small lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen). Lung Cancer 2005;48:251-61.
Vrdoljak 2001
Weatley-Price 2010
  • Wheatley-Price P, Ma C, Ashcroft LF, Nankivell M, Stephens RJ, White SC, et al. The strength of female sex as prognostic factor in small-cell lung cancer: a pooled analysis of chemotherapy trials from the Manchester Lung Group and Medical Research Council Clinical Trials Unit. Annals of Oncology 2010;21:232-7.
Weeks 2012
  • Weeks JC, Catalano PJ, Cronin A, Finkelman MD, Mack JW, Keating NL, et al. Patients' expectations about effects of chemotherapy for advanced cancer. New England Journal of Medicine 2012;367:1616-25.
Wolf 2004
Zelen 1973

References to other published versions of this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
  4. References to other published versions of this review
Agra 2003
  • Agra Varela Y, Pelayo Alvarez M, Sacristan M, Sacristan Rodea A, Serra C, Bonfill Cosp X. Chemotherapy versus best supportive care for extensive small cell lung cancer. Cochrane Database of Systematic Reviews 2003, Issue 4. [DOI: 10.1002/14651858.CD001990]
Pelayo 2009